Eaddie et al. [47] analyzed 155 CML patients at day 22 post-IM therapy, and observed that samples with high ABCB1 mRNA levels showed undesirable responses compared to samples with low ABCB1 mRNA levels. This evidence concerns the gene ABCB1 and chronic myelogenous leukemia, BCR-ABL1 positive.